{rfName}
Im

Indexed in

License and use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Moreno, RAuthorAlemany, RAuthor

Share

Publications
>
Article

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Publicated to:Journal Of Translational Medicine. 21 (1): 506- - 2023-07-27 21(1), DOI: 10.1186/s12967-023-04374-2

Authors: Wenthe, J; Eriksson, E; Hellström, AC; Moreno, R; Ullenhag, G; Alemany, R; Lövgren, T; Loskog, A

Affiliations

IDIBELL Inst Catala Oncol, Barcelona, Spain - Author
Lokon Pharm AB, Uppsala, Sweden - Author
Uppsala Univ Hosp, Dept Oncol, Uppsala, Sweden - Author
Uppsala Univ, Sci Life Lab, Rudbeck Lab, Dept Immunol Genet & Pathol, Dag Hammarskjoldsvag 20, S-75185 Uppsala, Sweden - Author

Abstract

Keywords

4-1bblAnimal experimentAnimal modelAntineoplastic activityArticleCancerCancer gene therapyCd40 antigenCd40lCell killingCell maturationCell viabilityControlled studyCytokineCytokinesDendritic cellDendritic cellsDown-regulationEnzyme activationEnzyme linked immunosorbent assayExpressionFemaleFlow cytometryGene expressionGene therapyGenetic therapyGeneticsGrowth-factor-betaHumanHuman cellHumansIl-2ImmunotherapyIn vitro studyIn vivo studyIncubation timeInterleukin 10Interleukin 2 receptorInterleukin-2Killer cells, naturalLokon oncolytic adenovirus 732MelanomaMetabolismMhc class-iMouseNatural killer cellNonhumanOncolytic adenovirusPeripheral blood mononuclear cellProtein targetingProteomicsReceptorResistanceT cellsT lymphocyteT-lymphocytesTransforming growth factor beta1TrimerizationTumor microenvironmentTumor necrosis factor receptor superfamily member 9Tumor volumeUnclassified drug

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal Of Translational Medicine due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 29/189, thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine, Research & Experimental.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 3, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-24, the following number of citations:

  • WoS: 3
  • Scopus: 4
  • OpenCitations: 3

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-24:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 9.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 9 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 1.5.
  • The number of mentions on the social network X (formerly Twitter): 3 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Sweden.